The magic mushroom compound psilocybin shows long-lasting antidepressant effects in a clinical trial, with patients reporting ...

Research on synthetic psychedelics progresses, and there's hope to prove psilocybin safe and effective in intractable ...

A single dose of a synthetic psilocybin was found to improve symptoms in patients with treatment-resistant depression.

In a phase 2 trial, about half of cancer patients reported sustained reductions in depression and anxiety 2 years after a single session of psilocybin plus psychological support.

Psilocybin, the active compound derived from psychedelic mushrooms, significantly delayed cellular aging and extended ...

Market reaction to recent readouts from Compass Pathways and Beckley Psytech/atai in treatment-resistant depression speaks to ...

A single dose of a synthetic form of psilocybin is safe and clinically meaningful in reducing treatment-resistant depression, topline results from a phase 3 trial suggest.

Could psychedelics be the next frontier in longevity research? Early data show psilocybin delays aging in lab tests.

A compound found in psychedelic mushrooms may have antiaging properties. Researchers at Baylor College of Medicine have found ...

June 17, 2025 For cancer patients with depression, psilocybin may provide lasting relief New research shows a single dose leads to 'robust' reductions in depression and anxiety up to 2 years ...

Psilocybin, a psychedelic compound contained in some varieties of mushrooms, has recently been found to be promising for the ...